Skip to content
DataLookout
Menu

NCT01885689

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 27 versions: 20 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words
    • Study completion pushed from Sep 21, 2026 to Aug 23, 2027
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Minor Study completion date: Oct 8, 2025 to Sep 21, 2026v25
  3. Minor Study completion date: Dec 30, 2024 to Oct 8, 2025v24
  4. Minor Study completion date: Dec 30, 2023 to Dec 30, 2024v23
  5. Notable Results first posted: Apr 4, 2023v22 Show 4 more changesShow less
    • Primary endpoint revised
    • Enrollment target: estimated 77 to confirmed 72
    • Primary completion date changed from estimate of Dec 30, 2023 to Dec 27, 2019
    • Secondary endpoints: 7 to 1
Show 14 earlier versionsHide 14 earlier versions
  1. Notable Primary and study completion dates: Dec 30, 2022 to Dec 30, 2023v21
  2. Notable Primary and study completion dates: Dec 30, 2021 to Dec 30, 2022v20
  3. Notable Start date: Jan 8, 2014 to Feb 10, 2014
    • Primary and study completion dates: Dec 2021 to Dec 30, 2021
    v19
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v16
  5. Notable Eligibility criteria expanded, about 33 words
    • Study description revised
    v14
  6. Minor Study completion date: Dec 2021
    • Start date: Jan 2014 to Jan 8, 2014
    • Interventions: allogeneic hematopoietic stem cell transplantation (Procedure), clofarabine (Drug), melphalan (Drug), sirolimus (Drug), tacrolimus (Drug) to Pharmacological Study (Other), allogeneic hematopoietic stem cell transplantation (Procedure), clofarabine (Drug), melphalan (Drug)…
    v13
  7. Notable Eligibility criteria expanded, about 60 words
    • Study description expanded, about 9 words
    • Study title expanded, about 3 words
    v12
  8. Minor Secondary endpoints revised (7)v10
  9. Minor Interventions: allogeneic hematopoietic stem cell transplantation (Procedure), clofarabine (Drug), laboratory biomarker analysis (Other), melphalan… to allogeneic hematopoietic stem cell transplantation (Procedure), clofarabine (Drug), melphalan (Drug), sirolimus (Drug), tacrolimus (Drug)v9
  10. Minor Study description expanded, about 1 wordv6
  11. Notable Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 1 of 7 entries
    v5
  12. Notable Eligibility criteria expanded, about 15 wordsv4 Show 4 more changesShow less
    • Primary endpoint revised
    • Interventions: allogeneic hematopoietic stem cell transplantation (Procedure), clofarabine (Drug), laboratory biomarker analysis (Other), melphalan (Drug) to allogeneic hematopoietic stem cell transplantation (Procedure), clofarabine (Drug), laboratory biomarker analysis (Other), melphalan…
    • Secondary endpoints revised (7)
    • Study description shortened, about 5 words
  13. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 2014 to Jan 2014
    • Site details revised
    v3
  14. Notable Start date: Dec 2013 to Jul 2014v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free Survival at 2 Years
Timeframe: From start of protocol treatment to death due to any cause, disease relapse/progression, or last follow-up, whichever comes first, assessed up to 2 years.

Secondary (1)

Overall Survival at 2 Years

Arms and interventions

Treatment (clofarabine, melphalan, transplant)Experimental

CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4. TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure.

Drugs: clofarabine, melphalan, tacrolimus, sirolimus

Procedures: allogeneic hematopoietic stem cell transplantation

Other: Pharmacological Study

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States